Literature DB >> 12504590

Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway.

Hiroaki Onda1, Peter B Crino, Hongbing Zhang, Ryan D Murphey, Luca Rastelli, Bonnie E Gould Rothberg, David J Kwiatkowski.   

Abstract

Cortical tubers are developmental brain malformations in the tuberous sclerosis complex (TSC) that cause epilepsy and autism in TSC patients whose pathogenesis is uncertain. Tsc2 null murine neuroepithelial progenitor (NEP) cells display persistent growth when growth factors are withdrawn, express GFAP at high levels, and have reduced expression of a set of early neuronal lineage markers. Tsc2 null NEP cells exhibit aberrant differentiation into giant cells that express both beta III-tubulin and GFAP and that are morphologically similar to giant cells in human tubers. Tsc2 null giant cells and tuber giant cells have similar transcriptional profiles. Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR. We conclude that giant cells in human tubers likely result from a complete loss of TSC2 expression and activation of an mTOR pathway during cortical development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12504590     DOI: 10.1006/mcne.2002.1184

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  51 in total

1.  Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin.

Authors:  Itzamarie Chévere-Torres; Jordan M Maki; Emanuela Santini; Eric Klann
Journal:  Neurobiol Dis       Date:  2011-07-30       Impact factor: 5.996

Review 2.  Nutrient sensing and TOR signaling in yeast and mammals.

Authors:  Asier González; Michael N Hall
Journal:  EMBO J       Date:  2017-01-17       Impact factor: 11.598

3.  Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target.

Authors:  Nisreen El-Hashemite; David J Kwiatkowski
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-30       Impact factor: 6.914

4.  Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.

Authors:  Bruno D Fonseca; Graham H Diering; Michael A Bidinosti; Kush Dalal; Tommy Alain; Aruna D Balgi; Roberto Forestieri; Matt Nodwell; Charles V Rajadurai; Cynthia Gunaratnam; Andrew R Tee; Franck Duong; Raymond J Andersen; John Orlowski; Masayuki Numata; Nahum Sonenberg; Michel Roberge
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

5.  Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis.

Authors:  O Jameel Shah; Tony Hunter
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 6.  The neurobiology of the tuberous sclerosis complex.

Authors:  Leah Marcotte; Peter B Crino
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 7.  Genetic and biologic classification of infantile spasms.

Authors:  Alex R Paciorkowski; Liu Lin Thio; William B Dobyns
Journal:  Pediatr Neurol       Date:  2011-12       Impact factor: 3.372

Review 8.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

9.  Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.

Authors:  Stephan Rüegg; Marianna Baybis; Hal Juul; Marc Dichter; Peter B Crino
Journal:  Epilepsy Res       Date:  2007-11-05       Impact factor: 3.045

Review 10.  Multiple amino acid sensing inputs to mTORC1.

Authors:  Mitsugu Shimobayashi; Michael N Hall
Journal:  Cell Res       Date:  2015-12-11       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.